Home > News > pSivida looks to advance in US market
March 17th, 2005
pSivida looks to advance in US market
Australian biotech pSivida is looking to boost its profile in the United States as it pushes its new silicon-based drug delivery technology, designed to substantially reduce side-effects in patients.
Speaking at a shareholders briefing in Sydney pSivida managing director Gavin Rezos said shrinking consumer tolerance for drug side effects over the past two decades had made its BioSilicon technology very lucrative.
Cloaked DNA nanodevices survive pilot mission: Successful foray opens door to virus-like DNA nanodevices that could diagnose diseased tissues and manufacture drugs to treat them April 22nd, 2014
Berkeley Lab Researchers Demonstrate First Size-based Chromatography Technique for the Study of Living Cells April 22nd, 2014
Amino-functionalized carbon nanotubes act as a carrier for nerve growth factor April 21st, 2014
Newly-Produced Bone Cement Able to Carry Medicine April 21st, 2014
Russia’s Nano-enabled Products Market to Witness Massive Growth February 8th, 2011
Adept Technology Announces Orders for Over $600K from Chinese Partner January 18th, 2011
Nanostart-held ItN Nanovation Receives Major Follow-on Order in Saudi Arabia November 29th, 2010
Homegrown Companies Developing Batteries for Clean Energy Storage November 2nd, 2010